Doctor of Microbiology and Biochemical Pharmacy, Chinese Academy of Medical Sciences & Peking Union Medical College. Beijing Science and Technology Rising Star, Beijing Top 100 Leading Talents, and Beijing High-level Innovation and Entrepreneurship Talents.
Responsible for the development, commercialization of the company's innovative drugs, and company operation. With more than 17 years of working experience in large pharmaceutical companies and innovative biotechnology companies, he has engaged in early drug development, clinical study, industrial production, and commercial development. He has a deep understanding of the development of the biomedical industry. and is skilled in operation of innovation-based enterprises. Shi has led Purun'ao to become a leading enterprise and a member of the inaugural batch of companies in Beijing Biopharmaceutical Industry Breakthrough Development Project (also known as G20 Project).
He has previously taken multiple executive positions including Executive Deputy General Manager of Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd., and Group R&D Director and BD Director of Harbin Gloria Pharmaceuticals Co.,Ltd. He launched the production of "Suhuang Zhike Capsules" with an annual sales of 2 billion yuan in Beijing, and led Yangzijiang Beijing Haiyan Pharmaceutical to become a G20 biopharmaceutical enterprise in Beijing.

David Liu, Ph.D., joined Vivo as a Principal with over 15 years of experience in Process R&D and CMC management in the pharmaceutical industry. He has led the development and implementation of novel and efficient chemical processes for tens of programs ranging from pre-IND to late stage Phase III. Prior to Vivo, he worked at STA-WuXi Apptec as Executive Director of Process Research & Development. Prior to STA, he was Director of Process Chemistry with Avista Pharma Solutions and Principal Research Investigator with Array BioPharma.

David received his B.S. and M.S. in Chemistry from Peking University and Ph.D. in Organic Chemistry from University of Pittsburgh. He completed his postdoctoral research at Texas A & M University.

Ms. Wang joined Bain Capital Private Equity in 2014. She is a Managing Director and a member of the Asia Pacific Private Equity team.

Prior to joining Bain Capital, Ms. Wang worked at Hony Capital where she closed transactions in buyout, minority investments and privatization in the healthcare sector.

Ms. Wang has a Master of Finance from Peking University and a BA in Economics from Fudan University.

Jiaqi is a founding member of Primavera Capital Group. He leads or co-leads the firm’s investments in healthcare and TMT sectors.

Jiaqi led or played an important role in a broad range of investment deals including ByteDance, LBX Pharmacy Chain, Jenscare Biotechnology, Avistone Pharmaceuticals, OptoMedic, Shukun Technology, Asia Medical, Symap Medical, OASIS International Hospital, Ubox Technology, as well as the cross-border joint acquisition of Iovate Health Sciences and the privatization of Shanda Games, Focus Media and Chemspec. He currently serves on the boards of LBX Pharmacy Chain, Jenscare Biotechnology, Avistone Pharmaceutical, Asia Medical and Iovate Health Sciences.

He previously worked at the Investment Banking Department of China International Capital Corporation.

Jiaqi holds a Bachelor of Arts in Economics from the University of Manchester and a Master of Science in Finance from Lancaster University.

Mr. Du is an Investment Director of SDIC Fund. He previously worded at Suzhou OrizaHoldings Corporation as investment analyst, investment manager and vice president. He was responsible for medical and health field investment. Mr. Du Participated in or led investment projects including Cstone Pharmaceutical (2616.HK), Ascentage Pharma, Biocytogen, Crystal Pharmatech, JW Therapeutics (2126.HK), Tyligand Bioscience, Avistone Biotechnology, etc. 

Mr. Du holds an MBA degree from Shanghai Advanced Institute of Finance of Shanghai Jiao Tong University, a master's degree in biotechnology from the University of Queensland, Australia, and a Bachelor's degree in biotechnology from Zhejiang Sci-Tech University.

He graduated from Beijing Institute of Technology with a Ph.D in Organic Chemistry. He is also a founding member of Avistone, and is in charge of development of innovative drugs. Like Shi Hepeng, he also possesses more than 17 years of experience, albeit principally in the development of innovative drugs. He has led numerous new drug projects, and is a key inventor of numerous clinical drug candidates, as well as a leader of several clinical studies.
Zhang has made significant achievements in the design of small-molecule targeted therapy, being a leader with rich experience in managing innovative teams.

One of the founding team members, responsible for promoting the company's pre-listing tutoring and subsequent IPO work, as well as post-listing company information disclosure, investor relations, corporate governance, equity investment, preparation for board of directors and shareholders' meetings, etc.

Ph.D in Applied Chemistry from Beijing Institute of Technology
One of the founding team members of Avistone, responsible for the clinical development of the company's innovative drugs. With more than 10 years of experience in innovative drug development, Head of clinical study of Vebreltinib project.
He has undertaken the "Major New Drug Development Project of Thirteenth Five-Year Plan" of the Ministry of Science and Technology and the Beijing "Clinical Research on Innovative Varieties and Key Technology Upgrades" project. He excels in clinical protocol design and project management.

Master degree in English from Tianjin Foreign Studies University
Responsible for the establishment and implementation of the company's talent and organizational development strategies, including recruitment, training and growth, remuneration and welfare, performance management and employee relationship.
With 10+ years of experience in pharmaceutical industry and human resources career, Fu has garnered vast experience in setting of strategies and recruitment, growth and retention of talents.